INSCRIPCIONES ABIERTAS - Formación en integración para facilitadores. Infórmate ahora

Contact

For inquiries regarding the utilization of ethnobotanicals, or in case you are experiencing an adverse situation or difficulty integrating and experience, please read this page. For inquiries regarding legal support , please read this page.

  • We don’t offer sessions of ayahuasca or iboga.
  • We don’t recommend centers or people who perform/do sessions.

    map mapa marcador ICEERS

    Office

    Carrer de Sepúlveda, 65 , Oficina 2, 08015 Barcelona España +34 931 88 20 99

    ICEERS Ibogaine Clinical Trial

    Our organization is committed to advancing clinical research and supports the development of evidence-informed policies. In 2020, ICEERS launched the first-ever Phase II clinical trial examining the efficacy of ibogaine for opioid dependence and detox from methadone. The clinical trial works to create a model that integrates ibogaine, substance use disorder therapy, and state-of-the-art harm reduction.

    Why the Clinical Trial?

    ICEERS was founded in 2009 after almost a decade of engagement and community building with the ibogaine medical subculture and destigmatization of iboga(ine) through educational efforts with the documentary Ibogaine – Rite of Passage. In 2020, our organization began the first-ever Phase II clinical trial exploring the safety and potential of ibogaine to treat opioid dependency. Conducted at the Sant Joan Hospital in Reus, Catalunya (Spain) with partial funding from the Catalan government, the study is testing a novel treatment protocol with ascending low doses of ibogaine to support 20 patients tapering off of methadone. The primary goal is to evaluate the safety and efficacy of ibogaine in the treatment of methadone withdrawal. If the protocol is successful, this will provide evidence to support its application with shorter-acting opioids, such as heroin. Learn more about the study design and dosing protocol.

    The interest in ibogaine as a treatment option for various mental health conditions has been steadily increasing. Prior investigation has indicated that ibogaine has promise for psychotherapy, substance use disorders (SUDs), and personal growth. But there is a difference between what anecdotal reports have shared and what can be replicated in a clinical environment. This clinical trial arose to expand the collective knowledge base on the potential of ibogaine as a treatment option and fill this important gap. The hope is that it supports sensible changes in policy and inspires the scientific community.

    clinical trial ibogaine

    Biocultural Conservation & Right Relationship

    Ibogaine is only one of the many compounds found within iboga (Tabernanthe iboga), known as “sacred wood” by the people of Gabon. T. iboga is now in a rapid decline in the wild. This is because of the increasing demand for ibogaine and iboga which results in illegal poaching and over-harvesting. 

    The majority of the ibogaine used in research or by treatment providers comes from iboga. However, it can also be extracted from Voacanga africana, another African tree. Some of the sustainability issues with ibogaine may be addressed by sourcing ibogaine from V. africana, cultivated iboga (exported following the Nagoya Protocol), or through developing synthetic options. The ibogaine for the ICEERS clinical trial is sourced from Voacanga africana.

    We have been working to assure the globalization of ibogaine happens in a way that strengthens local communities in Africa through right relationship and benefit sharing.  We have conducted a global ibogaine assessment including fieldwork in Gabon to look at the challenges presented by the increasing interest in iboga/ine and the collective aspirations of the people who have carried this knowledge. This initiative engaged with the international community to crowdsource opinions and ideas about what an ideal future looks like for iboga and ibogaine in global society.

    In addition, we have been partnering with Blessings of the Forest in Gabon who are dedicated to implementing anti-biopiracy and extraction mechanisms and a path towards equitable, community-based iboga sources with partners in Gabon. This effort became part of the Indigenous Medicine Conservation Fund in 2022.

    The interest in ibogaine as a treatment option for various mental health conditions has been steadily increasing. Prior investigation has indicated that ibogaine has promise for psychotherapy, substance use disorders (SUDs), and personal growth. But there is a difference between what anecdotal reports have shared and what can be replicated in a clinical environment. This clinical trial arose to expand the collective knowledge base on the potential of ibogaine as a treatment option and fill this important gap. The hope is that it supports sensible changes in policy and inspires the scientific community.

     

    Further Info on the Ibogaine Clinical Trial

    Further Materials on Iboga & Ibogaine

    A Special Thanks

    In 2022, ICEERS received the first-ever research grant from The Etheridge Foundation for our ibogaine and opioid dependence clinical trial. A special thanks to all of the public or non-profit entities (none of which are affiliated with the pharmaceutical industry) that donated to help make this study possible.

    Sponsors and Collaborators

    DISCLAIMER

    ICEERS takes care to ensure that the information presented on this website is accurate at the time of its publication. However, over time new scientific and medical information becomes available, and laws and legal enforcement polices change. In addition, laws and legal enforcement policies governing the use of substances discussed on this website vary from jurisdiction to jurisdiction. The reader is advised to carefully consult appropriate sources for the most current information on scientific, medical, and legal issues. Material on this website is not intended to and should not be used as a substitute for personal consultation with knowledgeable physicians and attorneys.
    The information on this website is offered for informational use only, and is not intended for use in diagnosing any disease or condition or prescribing any treatment whatsoever. The information on this website is not intended to encourage the use of ethnobotanicals. ICEERS specifically cautions against the use of ethnobotanicals in violation of the law, without appropriate professional guidance and monitoring, or without careful personal evaluation of potential risks and hazards. ICEERS specifically disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents of this website.

    © 2024 ALL RIGHTS RESERVED